Prevalence of Metabolic Syndrome in Organ Transplantation: A Review of the LiteratureValentina Vicennati1*, Antonio Daniele Pinna2, Maria Cristina Morelli2, Uberto Pagotto1 and Renato Pasquali1
- *corresponding Author:
- Dr. Valentina Vicennati
Division of Endocrinology and 2Liver and Multiorgan Transplant Unit
S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Tel: 0039 051 6364310
Fax: 0039 051-6363080
E-mail: [email protected]
Received Date: November 24, 2014; Accepted Date: January 20, 2015; Published Date: January 28, 2015
Citation: Vicennati V, Pinna AD, Morelli MC, Pagotto U, Pasquali R (2015) Prevalence of Metabolic Syndrome in Organ Transplantation: A Review of the Literature. Endocrinol Metab Synd 4:157. doi:10.4172/2161-1017.1000157
Copyright: © 2015 Vicennati V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The clinical features of the Metabolic Syndrome (MS) as risk factors for transplantation have been cited separately and extensively in the transplant literature. There are few studies in literature evaluating the prevalence of MS before and after solid organ transplantation. MS puts transplant patients at risk in in two ways: 1) MS is one more risk factor to be considered in the pretransplantation workup; and 2) the combined risk of cardiovascular disease post-transplantation as a side effect of immunosuppressive medication together with the risk from cardiovascular disease stemming from the MS might put a post-transplantation patient at vastly increased risk for a cardiovascular event. There are several reports on the treatment of MS expecially after transplantation; from lifestyle changes to drug therapies. However, to now, guidelines about management of these patients are lacking.